Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zylacta
- Development stage
- Unknown
- Lead developer
- Zylacta
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
Zylacta is a probiotic formulation typically containing a combination of *Lactobacillus acidophilus* and *Lactobacillus bulgaricus*. It is primarily used as a dietary supplement to support gastrointestinal health and to restore the natural balance of intestinal flora, which can be disrupted by factors such as antibiotic use, illness, or poor diet. The mechanism of action involves the colonization of the gut by these beneficial bacteria, which produce lactic acid and other antimicrobial substances that inhibit the growth of pathogenic microorganisms. Additionally, these probiotics help maintain the integrity of the intestinal mucosal barrier and modulate the local immune response. Zylacta is often indicated for the management of diarrhea, including antibiotic-associated diarrhea, and for general digestive support.
- Brand names
- Zylacta
- Other names
- Lactobacillus acidophilusLactobacillus bulgaricus
Beyond the preview
Go deeper on Zylacta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zylacta.